Genelux (GNLX) Expected to Post Quarterly Earnings on Wednesday

Genelux (NASDAQ:GNLX) is projected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Genelux to announce earnings of ($0.20) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, analysts expect Genelux to post ($0.81) EPS for the current fiscal year and ($0.68) EPS for the next fiscal year.

Genelux Price Performance

Shares of NASDAQ GNLX opened at $2.08 on Monday. The firm has a market cap of $94.10 million, a PE ratio of -2.42 and a beta of 0.68. Genelux has a 12-month low of $1.86 and a 12-month high of $8.53. The company’s fifty day simple moving average is $2.46 and its 200 day simple moving average is $2.69.

Insider Buying and Selling

In other news, CEO Thomas Zindrick sold 34,463 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $2.67, for a total transaction of $92,016.21. Following the completion of the sale, the chief executive officer owned 1,226,427 shares in the company, valued at $3,274,560.09. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Yong Yu sold 9,683 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $2.75, for a total value of $26,628.25. Following the transaction, the insider directly owned 258,688 shares in the company, valued at $711,392. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 47,822 shares of company stock valued at $129,482 in the last three months. Insiders own 7.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Wall Street Zen raised shares of Genelux from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 20th. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Thursday, October 15th. Finally, Lucid Cap Mkts upgraded Genelux to a “strong-buy” rating in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Genelux Company Profile

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer.

Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.

Founded in 2001 and headquartered in San Diego, California, Genelux conducts its research and clinical development activities primarily in the United States.